Breaking News Instant updates and real-time market news.

IMMU

Immunomedics

$14.33

-0.02 (-0.14%)

, SGEN

Seattle Genetics

$76.01

3.38 (4.65%)

17:26
09/29/19
09/29
17:26
09/29/19
17:26

Piper Jaffray says some may be disappointed by Immunomedics TROPHY response rate

Piper Jaffray analyst Joseph Catanzaro notes that Immunomedics (IMMU) presented interim data from the Phase II TROPHY study of sacituzumab govitecan in postchemo/CPI urothelial bladder cancer at ESMO. Overall, the response rate of 29% is consistent with prior Phase I data, but he does believe some could be disappointed by this number as it relates to Seattle Genetics' (SGEN) 44% ORR for EV. Catanzaro would await more mature data before drawing any definitive conclusions on the competitive positioning of sacituzumab and EV in post-chemo/IO UBC, but ultimately believes the SC ORR in a larger cohort is approvable and that both drugs will play important roles in this landscape. He reirerates an Overweight rating and $20 price target on Immunomedics's shares.

IMMU

Immunomedics

$14.33

-0.02 (-0.14%)

SGEN

Seattle Genetics

$76.01

3.38 (4.65%)

  • 02

    Oct

IMMU Immunomedics
$14.33

-0.02 (-0.14%)

08/20/19
CANT
08/20/19
INITIATION
Target $28
CANT
Overweight
Cantor Fitzgerald starts Immunomedics at Overweight, sees approval forthcoming
As previously reported, Cantor Fitzgerald analyst Varun Kumar initiated Immunomedics with an Overweight rating and $28 price target. The current stock price reflects risks around FDA approval in triple-negative breast cancer due to the company receiving a complete response letter earlier this year, though he predicts sacituzumab govitecan will get regulatory approval since he views the issues raised in the CRL as not related to pre/clinical data. He also thinks, based on checks with key opinion leading doctors, that sacituzumab should have strong commercial uptake.
08/20/19
08/20/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Immunomedics (IMMU) initiated with an Overweight at Cantor Fitzgerald. 2. PayPal (PYPL) initiated with a Buy at Rosenblatt while Square (SQ) was initiated with a Neutral. 3. Sunrun (RUN), Vivint Solar (VSLR), and Sunnova Energy (NOVA) initiated with an Overweight at KeyBanc. 4. Spotify (SPOT) initiated with an Equal Weight at Consumer Edge. 5. Silk Road Medical (SILK) initiated with a Buy at Argus. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/10/19
PIPR
09/10/19
NO CHANGE
PIPR
Overweight
Safety signals arise for potential Immunomedics competitor, says Piper Jaffray
Daiichi today reported updated Phase I data for its TROP2 antibody drug conjugate DS-1062 in non-small cell lung cancer, and while the drug's efficacy continues to impress, there do appear to be some safety signals popping up, Piper Jaffray analyst Joseph Catanzaro tells investors in a research note. Specifically, dose-limiting toxicities associated with skin rash/stomatitis were reported, which is notable as development of Pfizer's (PFE) TROP2 antibody drug conjugate was discontinued for excess skin rash and mucosa toxicity, adds the analyst. These data may or may not dampen concerns around DS-1062 being a competitive threat to Immunomedics' sacituzumab, says Catanzaro. However, he continues to believe Immunomedics is "very well-positioned" within triple-negative breast cancer and urothelial bladder cancer. The analyst reiterates an Overweight rating on the shares with a $20 price target. Following Daiichi's data, shares of Immunomedics are up 8% to $14.30.
09/10/19
JEFF
09/10/19
NO CHANGE
JEFF
Buy
Immunomedics competitor shows 'impressive' efficacy, AEs cause concern, says Jefferies
Jefferies analyst Chris Howerton says that Immunomedics competitor DS-1062 showed "impressive" efficacy of 70%-plus cORR at RP2D, but he notes that n=7 is "quite small," and baseline characteristics could be different. Importantly, the analyst points out that one patient died of respiratory failure, and four reported potential ILD since data cutoff, including one death. Overall, he does not view DS-1062 as near-term comparable to IMMU-132's current pipeline. Howerton reiterates a Buy rating and $22 price target on Immunomedics' shares.
SGEN Seattle Genetics
$76.01

3.38 (4.65%)

09/12/19
OPCO
09/12/19
UPGRADE
OPCO
Outperform
Seattle Genetics upgraded to Outperform from Perform at Oppenheimer
09/12/19
09/12/19
UPGRADE
Target $82

Outperform
Seattle Genetics upgraded to Outperform at Oppenheimer
As previously reported, Oppenheimer analyst Silvan Tuerkcan upgraded Seattle Genetics to Outperform from Perform based on his review of pipeline assets Enfortumab Vedotin and tucatinib that focus on less competitive later lines of treatment with strong data. The analyst also notes that recent weakness in the shares presents an attractive entry point ahead of several pipeline catalysts. Tuerkcan raised his price target on the stock to $82 from $77.
09/27/19
GSCO
09/27/19
UPGRADE
Target $100
GSCO
Buy
Seattle Genetics upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Salveen Richter upgraded Seattle Genetics to Buy from Neutral and raised his price target for the shares to $100 from $78. The stock closed Thursday down 99c to $72.63. With continued Adcetris growth in Hodgkin's lymphoma and peripheral T cell lymphoma, the analyst expects "multiple near-term pipeline drivers to cement" the company's transition into a multi-product oncology company. He expects approval of enfortumab vedotin by the March 15, 2020 action data and is positive on Seattle's two-late stage assets, tucatinib in HER2+ metastatic breast cancer and tisotumab vedotin in metastatic cervical cancer, with results by year-end 2019 and the first half of 2020, respectively.
09/27/19
09/27/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Western Union (WU) upgraded to Buy from Neutral at Guggenheim with analyst Jeff Cantwell citing what he called the company's "positive" investor day where management outlined "a solid 3-year growth trajectory." 2. Applied Genetic (AGTC) upgraded to Outperform from Market Perform at BMO Capital with analyst Matthew Luchini saying the early XLRP data suggest potential for vision stabilization in peripherally treated patients and vision improvement in centrally treated patients. 3. Seattle Genetics (SGEN) upgraded to Buy from Neutral at Goldman Sachs with analyst Salveen Richter saying with continued Adcetris growth in Hodgkin's lymphoma and peripheral T cell lymphoma, he expects "multiple near-term pipeline drivers to cement" the company's transition into a multi-product oncology company. 4. Match Group (MTCH) upgraded to Outperform from In Line at Evercore ISI. 5. Texas Instruments (TXN) upgraded to Buy from Neutral at BofA/Merrill with analyst Vivek Arya saying he is positive on Texas Instruments' market share gains, stronger free cash flow returns, stronger positioning in growth areas such as 5G, Internet-of-Things, and Electric vehicles. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

SWDAF

Software AG

$0.00

(0.00%)

19:33
10/17/19
10/17
19:33
10/17/19
19:33
Upgrade
Software AG rating change  »

Software AG upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBR

Petrobras

$14.43

-0.22 (-1.50%)

18:57
10/17/19
10/17
18:57
10/17/19
18:57
Hot Stocks
Petrobras reports Q3 production 2.878M boepd, up 9.3% »

Petrobras said it posted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

MRTN

Marten Transport

$21.52

0.31 (1.46%)

, ISRG

Intuitive Surgical

$529.22

-1.25 (-0.24%)

18:49
10/17/19
10/17
18:49
10/17/19
18:49
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

MRTN

Marten Transport

$21.52

0.31 (1.46%)

ISRG

Intuitive Surgical

$529.22

-1.25 (-0.24%)

ETFC

E-Trade

$39.04

0.02 (0.05%)

WAL

Western Alliance

$46.24

0.53 (1.16%)

TEAM

Atlassian

$122.43

-1.91 (-1.54%)

PRTK

Paratek Pharmaceuticals

$3.46

0.05 (1.47%)

GIL

Gildan Activewear

$35.38

0.095 (0.27%)

BDN

Brandywine Realty

$14.68

0.13 (0.89%)

EXPO

Exponent

$70.82

1.34 (1.93%)

WDFC

WD-40

$182.75

2.41 (1.34%)

VICR

Vicor Corporation

$32.78

1.16 (3.67%)

OZK

Bank OZK

$28.32

0.03 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 19

    Oct

  • 27

    Oct

  • 29

    Oct

  • 30

    Oct

  • 31

    Oct

  • 31

    Oct

  • 06

    Nov

  • 13

    Nov

  • 13

    Nov

  • 19

    Nov

  • 19

    Nov

  • 22

    Nov

ARWR

Arrowhead

$36.61

2.11 (6.12%)

, AMGN

Amgen

$203.60

0.32 (0.16%)

18:43
10/17/19
10/17
18:43
10/17/19
18:43
Hot Stocks
Arrowhead CEO: We can silence a single gene »

In an interview on…

ARWR

Arrowhead

$36.61

2.11 (6.12%)

AMGN

Amgen

$203.60

0.32 (0.16%)

JNJ

Johnson & Johnson

$136.20

1 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

  • 07

    Dec

SXT

Sensient

$66.57

0.4 (0.60%)

18:32
10/17/19
10/17
18:32
10/17/19
18:32
Hot Stocks
Sensient raises quarterly dividend 8.3% to 39c per share »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

T

AT&T

$37.82

0.03 (0.08%)

18:31
10/17/19
10/17
18:31
10/17/19
18:31
Periodicals
HBO Max to stream Studio Ghibli films, Reuters says »

AT&T's upcoming…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 29

    Oct

  • 18

    Nov

  • 19

    Nov

OMAB

OMA

$52.10

0.47 (0.91%)

18:19
10/17/19
10/17
18:19
10/17/19
18:19
Earnings
OMA reports Q3 net income MXN858M vs. MXN725M last year »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

MAR

Marriott

$120.57

-0.55 (-0.45%)

18:13
10/17/19
10/17
18:13
10/17/19
18:13
Periodicals
Marriott near deal for Elegant Hotels valued up to GBP1 / shr, Bloomberg says »

The report states that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

SPY

SPDR S&P 500 ETF Trust

$299.19

0.78 (0.26%)

, SPX

S&P 500

$0.00

(0.00%)

18:08
10/17/19
10/17
18:08
10/17/19
18:08
General news
NY Fed's Williams Condition in money markets highly volatile over past month »

Williams says:…

SPY

SPDR S&P 500 ETF Trust

$299.19

0.78 (0.26%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$36.20

-0.45 (-1.23%)

17:47
10/17/19
10/17
17:47
10/17/19
17:47
Periodicals
GM strike to continue until deal with UAW is ratified, WSJ says »

United Auto Workers union…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

T

AT&T

$37.82

0.03 (0.08%)

17:37
10/17/19
10/17
17:37
10/17/19
17:37
Periodicals
AT&T, Elliott Management in talks to resolve activist campaign, WSJ reports »

AT&T is in talks with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 29

    Oct

  • 18

    Nov

  • 19

    Nov

WAL

Western Alliance

$46.24

0.53 (1.16%)

17:27
10/17/19
10/17
17:27
10/17/19
17:27
Earnings
Western Alliance reports Q3 EPS $1.24, consensus $1.19 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 30

    Oct

  • 31

    Oct

  • 06

    Nov

RNLSY

Renault

$0.00

(0.00%)

17:25
10/17/19
10/17
17:25
10/17/19
17:25
Downgrade
Renault rating change at Deutsche Bank »

Renault downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOVE

Lovesac

$19.10

0.63 (3.41%)

17:24
10/17/19
10/17
17:24
10/17/19
17:24
Hot Stocks
Park West Management reports 5.1% passive stake in Lovesac »

Park West Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

T

AT&T

$37.82

0.03 (0.08%)

17:24
10/17/19
10/17
17:24
10/17/19
17:24
Periodicals
Breaking Periodicals news story on AT&T »

AT&T in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 29

    Oct

  • 18

    Nov

  • 19

    Nov

ATVI

Activision Blizzard

$55.60

0.01 (0.02%)

17:16
10/17/19
10/17
17:16
10/17/19
17:16
Hot Stocks
Activision says Call of Duty to get 'battle pass' feature, 'not loot box system' »

Activision's Call of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 07

    Nov

BDN

Brandywine Realty

$14.68

0.13 (0.89%)

17:11
10/17/19
10/17
17:11
10/17/19
17:11
Hot Stocks
Brandywine Realty sees FY19 year-end core occupancy at 94%-95% »

Also sees FY20 year-end…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

BDN

Brandywine Realty

$14.68

0.13 (0.89%)

17:10
10/17/19
10/17
17:10
10/17/19
17:10
Hot Stocks
Brandywine Realty reports Q3 same-store net operating income up 0.6% »

Reports Q3 occupancy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

BDN

Brandywine Realty

$14.68

0.13 (0.89%)

17:09
10/17/19
10/17
17:09
10/17/19
17:09
Earnings
Brandywine Realty sees FY20 initial FFO $1.41-$1.51, consensus $1.46 »

Sees FY20 same-store net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

GIL

Gildan Activewear

$35.38

0.095 (0.27%)

17:08
10/17/19
10/17
17:08
10/17/19
17:08
Earnings
Gildan Activewear cuts FY19 adj. EPS view to $1.65-$1.70 from $1.95-$2.00 »

Consensus $1.97. Cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDN

Brandywine Realty

$14.68

0.13 (0.89%)

17:07
10/17/19
10/17
17:07
10/17/19
17:07
Earnings
Brandywine Realty narrows FY19 FFO guidance to $1.41-$1.43 from $1.40-$1.44 

Consensus $1.42.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

BDN

Brandywine Realty

$14.68

0.13 (0.89%)

17:07
10/17/19
10/17
17:07
10/17/19
17:07
Earnings
Brandywine Realty reports Q3 FFO 36c, consensus 36c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

GIL

Gildan Activewear

$35.38

0.095 (0.27%)

17:06
10/17/19
10/17
17:06
10/17/19
17:06
Earnings
Gildan Activewear sees Q3 adjusted EPS roughly 53c, consensus 57c »

Sees Q3 revenue about…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ISRG

Intuitive Surgical

$529.22

-1.25 (-0.24%)

17:04
10/17/19
10/17
17:04
10/17/19
17:04
Hot Stocks
Intuitive Surgical increases FY19 procedure growth view to 17%-18% from 16%-17% »

Sees FY19 gross profit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 19

    Oct

SAVE

Spirit Airlines

$36.70

0.645 (1.79%)

17:01
10/17/19
10/17
17:01
10/17/19
17:01
Hot Stocks
Spirit Airlines announces $250M global HQ investment »

Spirit Airlines announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 29

    Oct

  • 30

    Oct

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.